共 143 条
[11]
Bloomer J.C., Woods F.R., Haddock R.E., Lennard, Tucker G.T., The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes, British Journal of Clinical Pharmacology, 33, pp. 521-523, (1992)
[12]
Bluhm R.E., Wilkinson G.R., Shelton R., Branch R.A., Genetically determined drug-metabolizing activity and desipramine associated cardiotoxicity: a case report, Clinical Pharmacology and Therapeutics, 53, pp. 89-95, (1993)
[13]
Brockmoller J., Staffeldt B., Roots I., Evaluation of proposed sulphoxidation pathways of carbocysteine in man by HPLC quantification, European Journal of Clinical Pharmacology, 40, pp. 387-392, (1991)
[14]
Broly F., Libersa C., Lhermitte M., Dupuis B., Inhibitory studies of mexiletine and dextromethorphan oxidation in human liver microsomes, Biochemical Pharmacology, 39, pp. 1045-1053, (1990)
[15]
Broly F., Vandamme N., Libersa C., Lhermitte M., The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation, British Journal of Clinical Pharmacology, 32, pp. 459-466, (1991)
[16]
Brosen K., Gram L.F., Clinical significance of the sparteine/debrisoquine oxidation polymorphism, European Journal of Clinical Pharmacology, 36, pp. 537-547, (1989)
[17]
Brosen K., Gram L.F., Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine, European Journal of Clinical Pharmacology, 37, pp. 155-160, (1989)
[18]
Buchert E., Woosley R.L., Clinical implications of variable antiarrhythmic drug metabolism, Pharmacogenetics, 2, pp. 2-11, (1992)
[19]
Burchill B., Coughtrie M.W.H., UDP-Glucuronyltransferases, Pharmacology and Therapeutics, 43, pp. 261-289, (1989)
[20]
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arryhthmia suppression after myocardial infarction, New England Journal of Medicine, 321, pp. 406-412, (1989)